<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760616</url>
  </required_header>
  <id_info>
    <org_study_id>HE-201102</org_study_id>
    <nct_id>NCT01760616</nct_id>
  </id_info>
  <brief_title>Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy</brief_title>
  <official_title>A Prospective, Multicenter, Open-labeled, Parallel -Controlled Clinical Study Investigating Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qidong Gaitianli Medicines Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression
      of hepatocarcinoma after non-radical hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Multicenter, Open-labeled, Parallel -controlled Clinical Study, to evaluate
      the efficacy and safety of Huaier Granule for prevention of disease progression of
      hepatocarcinoma after non-radical hepatectomy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to significant progression after surgery</measure>
    <time_frame>3 years</time_frame>
    <description>Time to significant progression after surgery, including recurrence of local tumor, intrahepatic and extrahepatic metastasis, etc; and to evaluation of postoperative survival period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECOG and QLQ-C30 scores</measure>
    <time_frame>Week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144</time_frame>
    <description>On week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, assess the scores of Eastern Cooperative Oncology Group(ECOG) and quality of life questionnaire(QLQ)-C30 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iconography assessment</measure>
    <time_frame>Week 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144</time_frame>
    <description>On week 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, give examination of B ultrasonic for Liver, X-ray for chest. If there is a suspected recurrence or metastases, will give enhancement CT/MRI examination for liver and chest; if no recurrence or metastases, will at least give enhancement CT/MRI examination for liver and chest every year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-fetoprotein quantitation and related biochemical indicators</measure>
    <time_frame>Week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144</time_frame>
    <description>On week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, monitor Alpha-fetoprotein quantitation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1680</enrollment>
  <condition>Hepatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: adjuvant therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: ≥ 18 and ≤ 75 years, both male and female;

          2. Non-radical hepatectomy has been performed for hepatocellular carcinoma;

          3. The hepatocellular carcinoma has been confirmed by pathological examination;

          4. The liver and kidney function satisfies the following conditions within 15 days after
             surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic
             transaminase(ALT)&lt;3 upper limit of normal(ULN), total bilirubin ≤2 ULN, serum
             creatinine &lt;1.5 ULN;

          5. Other laboratory tests meet the following requirements within 15 days after surgery
             (excluding day 15): Hb≥9g/dl, platelet count≥60×109/L, neutrophil count&gt; 2.5×109/L;

          6. The expected survival time ≥12 weeks;

          7. The subjects volunteer to sign the informed consent.

        Exclusion Criteria:

          1. Non-hepatocellular carcinoma patients;

          2. Those who received radical hepatectomy;

          3. Those with hepatic decompensation;

          4. Pregnant or lactating women;

          5. Those with HIV infection or AIDS-associated diseases;

          6. Those with severe acute and chronic diseases, such as infection, diabetes cardiac
             insufficiency, pulmonary insufficiency, renal insufficiency;

          7. Those who can not take drugs by oral route; or those develop serious adverse drug
             reaction;

          8. Drug abusers or those with psychological or mental diseases that may interfere with
             study compliance;

          9. Conditions that are considered not suitable for this study investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College, Huazhong</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huaier Granule;</keyword>
  <keyword>After non-radical hepatectomy;</keyword>
  <keyword>Prevention of Disease Progression of Hepatocarcinoma;</keyword>
  <keyword>Safety.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

